STOCK TITAN

Daxor Corporation - DXR STOCK NEWS

Welcome to our dedicated page for Daxor Corporation news (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on Daxor Corporation stock.

Daxor Corporation Common Stock (DXR) represents a pioneering medical instrumentation and biotechnology company focused on the accurate measurement of blood volume. Daxor develops and markets the BVA-100 (Blood Volume Analyzer), which stands as the first FDA-cleared diagnostic tool capable of providing precise, objective quantification of blood volume status and composition compared to patient-specific norms. This technology is pivotal across a wide range of medical conditions.

The BVA-100 has revolutionized blood volume measurement, a practice that has historically been prone to lengthy and inaccurate testing processes. Traditional methods often took 4 to 8 hours and yielded inconsistent results. In contrast, the BVA-100 can deliver accurate and reliable measurements quickly, enhancing the capabilities of physicians who previously had to rely on less precise tests that measured blood thickness, often leading to misleading outcomes in critical medical situations.

Daxor Corporation, headquartered in New York, is at the forefront of medical technology and innovation. The company's recent achievements include the development of the next generation of Blood Volume Analyzer Systems, securing further research patents, and producing excellent clinical outcomes. These advancements are not only enhancing the quality of patient care but also strengthening the company's market position.

Financially, Daxor has shown robust growth, with unaudited revenue climbing 229.1% in the first two months of 2024 year-on-year. The company's strong start to 2024 is indicative of its commitment to innovation and excellence. Daxor is also actively engaged in strategic partnerships and investor relations, with Bret Shapiro serving as the Senior Managing Partner at CORE IR, ensuring transparent and effective communication with investors and stakeholders.

In addition to its technological developments, Daxor is also a notable presence in the medical community, participating in significant events such as the Premier Event for Cardiovascular Industry Leaders and Clinicians. The company's research and publications, such as those presented at the American College of Cardiology Scientific Sessions and in the American Heart Journal, underscore its dedication to advancing medical knowledge and practice.

Rhea-AI Summary
Daxor Corporation (DXR) receives a second patent (U.S. Patent No. 11,862,311 B2) from the United States Patent and Trademark Office for a distinctive clinical guidance system for blood volume management. The system utilizes unique blood volume metrics and related clinical measures to create support guidance for fluid management interventions, targeting common and costly conditions such as heart failure, critical care, hypertension, surgical blood loss, and sepsis. Daxor's Chief Scientific Officer, Jonathan Feldschuh, highlights that the new patented system makes fluid management decisions significantly easier, driving better outcomes and empowering clinicians to make more effective treatment decisions. Daxor's CEO and President, Michael Feldschuh, emphasizes the company's mission to advance healthcare by enabling optimal fluid management and equipping physicians with tools for more effective diagnosis and treatment, ensuring a distinct advantage in the market with next-generation products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
none
-
Rhea-AI Summary
Daxor Corporation (Nasdaq: DXR) has submitted its next-generation blood volume analyzer - Daxor BVA - to the U.S. Food and Drug Administration (FDA) via the 510(k)/CLIA-waiver dual submission pathway. Potential clearance is expected during the first half of 2024. The new Daxor BVA device directly quantifies the intravascular blood, red blood cell and plasma volume, providing clinicians with actionable information to achieve optimal fluid management for their patients. Compared to the current Daxor BVA-100 system, the new Daxor BVA is designed to be three times faster, simpler to operate, completely portable, and capable of performing bedside analysis, making it easier for healthcare providers to integrate this innovative diagnostic into their clinical workflow. The CEO and President, Michael Feldschuh, stated that the new analyzer will significantly improve care and outcomes in medicine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
none
-
Rhea-AI Summary
Daxor Corporation (Nasdaq: DXR) Announces Positive Results from NIH-Sponsored Study at AHA Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.05%
Tags
none
Rhea-AI Summary
Daxor Corporation (Nasdaq: DXR) announces the granting of a patent for remote blood volume monitoring using smartwatches and wearable devices. The patent covers methods for monitoring patients with various medical conditions, ensuring ongoing care is optimized based on evolving blood volume status. Daxor's Chief Scientific Officer highlights the significance of the patent in protecting innovations in applying blood volume measurement to specific medical conditions and situations. The company's CEO emphasizes the focus on innovation and next-generation technologies, supported by funding from the NIH and DoD, to add significant intellectual property assets for future product development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.79%
Tags
none
-
Rhea-AI Summary
Leading clinicians highlight significant outcome improvements with Daxor's blood volume analysis innovative technology
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
none
-
Rhea-AI Summary
Daxor Corporation announces new data validating the benefits of its BVA-100 diagnostic blood test for ambulatory patients with advanced heart failure.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
none
Rhea-AI Summary
Daxor Corporation has been accepted into the NIH Catalyze Preclinical Services Program, supporting the development of its non-nuclear fluorescent blood volume analyzer device. This initiative aims to improve outcomes for patients and expand the use of Daxor's technology in various clinical settings. Daxor will receive support and funding from third-party labs for preclinical work towards an FDA submission. This is separate from the ongoing initiative to launch a next-generation bedside analyzer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.39%
Tags
none
-
Rhea-AI Summary
Daxor's blood volume technology featured at scientific session. New data shows benefits of blood volume measurement in managing congestion. BVA guided treatment reduces heart failure readmissions by 56%, mortality by 82%, and length of stay by 57%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
none
-
Rhea-AI Summary
Daxor Corporation (NASDAQ: DXR) will be exhibiting at the MedAxiom CV Transforum Fall’23 Conference, showcasing their blood volume analysis technology. BVA guided care has been shown to significantly improve patient outcomes, with reductions in mortality and readmissions. The technology provides clinicians with 98% accurate data to optimize treatment plans and reduce costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.76%
Tags
none
Rhea-AI Summary
Daxor Corporation receives $305K NIH grant for sepsis fluid optimizer development
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of Daxor Corporation (DXR)?

The current stock price of Daxor Corporation (DXR) is $9.2842 as of November 22, 2024.

What is the market cap of Daxor Corporation (DXR)?

The market cap of Daxor Corporation (DXR) is approximately 44.9M.

What does Daxor Corporation specialize in?

Daxor Corporation specializes in medical instrumentation and biotechnology, with a focus on precise blood volume measurement using their BVA-100 system.

What is the BVA-100?

The BVA-100 is a Blood Volume Analyzer, the first FDA-cleared diagnostic tool that provides accurate quantification of blood volume and composition.

How has the BVA-100 improved blood volume measurement?

The BVA-100 provides quick, accurate, and reliable blood volume measurements, overcoming the lengthy and inaccurate traditional methods.

What are some recent achievements of Daxor Corporation?

Recent achievements include the development of the next generation Blood Volume Analyzer Systems, securing further research patents, and producing excellent clinical outcomes.

How has Daxor performed financially in early 2024?

Daxor reported a strong start to 2024 with unaudited revenue climbing 229.1% in the first two months year-on-year.

Who is the Investor Relations Contact at Daxor Corporation?

Bret Shapiro, the Senior Managing Partner at CORE IR, is the Investor Relations Contact for Daxor Corporation.

What kind of medical events does Daxor participate in?

Daxor participates in significant medical events like the Premier Event for Cardiovascular Industry Leaders and Clinicians.

Where has Daxor Corporation published its research findings?

Daxor has presented data at the American College of Cardiology Scientific Sessions and published research in the American Heart Journal.

What is the significance of the BVA-100 in medical practice?

The BVA-100 provides physicians with accurate blood volume data, improving diagnosis and treatment in various medical and surgical situations.

Where is Daxor Corporation headquartered?

Daxor Corporation is headquartered in New York.

Daxor Corporation

Nasdaq:DXR

DXR Rankings

DXR Stock Data

44.94M
2.10M
56.52%
2.01%
0.26%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States of America
NEW YORK